Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in patients ages 12 and older with CSU.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The condition is linked to Type 2 inflammation, which Dupixent helps target by blocking certain immune signaling pathways. The injection is already approved for CSU in several other countries ...

About Dupixent Dupixent (dupilumab) is an injection administered under the ... Dupixent is administered every two weeks based on weight (200 mg for adolescents ≥30 to <60 kg, 300 mg for ...